HIT Consultant
OCTOBER 13, 2024
Best practices for managing pharmaceutical data Again, there are no simple solutions for streamlining data management in the pharmaceutical industry. Manage Data Sensitivity Pharmaceutical companies deal with highly sensitive data, but the risks that it poses can vary.
Bill of Health
OCTOBER 26, 2023
Global solidarity requires cooperation between governments, while national solidarity involves cooperation within a state to address common challenges and achieve shared goals. Solidarity operates at two intersecting levels. That has created deep inequities in access to health products that can save lives.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill of Health
MAY 5, 2023
When there is a compulsory license in place, a government of a country allows a third party to manufacture and distribute a product protected by patents, without the consent of the patent owner. The Proposal A compulsory license allows third parties to use a patent without asking prior permission from the owner of said patent.
HIT Consultant
OCTOBER 25, 2022
In addition to these challenges specific to their industry, pharma companies are all also presented with classic barriers to implementation. For example, the need for a flexible infrastructure to collect data, verify data, run applications, and perform data governance.
Dot Compliance
MAY 3, 2024
In the pharmaceutical industry, the importance of regulatory compliance extends beyond fulfilling legal obligations. Compliance can be streamlined with the help of an electronic quality management system (eQMS) that incorporates regulatory standards into every operational aspect of a pharmaceutical organization.
Bill of Health
AUGUST 29, 2022
government funding, announced that it felt “a special obligation … to use our resources to bring this pandemic to an end as quickly as possible.” government purchased millions of doses of Moderna’s mRNA vaccine, along with large quantities of vaccines manufactured by Pfizer. By Jorge L. Updating” the Pledge. From 2020 to 2022, the U.S.
Bill of Health
JUNE 26, 2023
By Aparajita Lath For over 100 years, policy makers and pharmaceutical manufacturers in the U.S. have debated whether the government should produce drugs and biologics. Until now, private industry has largely won– but that may be changing, due to a recent California initiative. Now, the tide is turning.
Expert insights. Personalized for you.
98 
Let's personalize your content